Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Oyster Point Pharma Inc (NQ: OYST )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oyster Point Pharma Inc

OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
From Kahn Swick & Foti, LLC
Via Business Wire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Oyster Point Pharma, Inc.
Via GlobeNewswire
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development 
Via Spotlight Growth
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET 
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.